Trials / Completed

CompletedNCT02352051

Effects of Atx and Oros-mph on Executive Functions

Effects of Atomoxetine and Oros-mph on Executive Functions in Patients With Combined Type Attention Deficit Hyperactivity Disorder

Status: Completed
Phase: Phase 4
Study type: Interventional
Enrollment: 43 (actual)

Sponsor: TC Erciyes University · Academic / Other
Sex: All
Age: 7 Years – 12 Years
Healthy volunteers: Not accepted

Summary

Detailed description

The aim of this study was to evaluate and compare the effects of Atomoxetine(ATX) and osmotic release oral system-methylphenidate (OROS-MPH) therapies on executive functions, activities, treatment response time and adverse effects based on discernible clinical effects in children with combined type attention deficit-hyperactivity disorder (ADHD). In this study, the functional capabilities of the patients who clinically responded well to therapy were assessed simultaneously with clinical response that may appear at different time periods and the treatment groups were compared in patients who responded to therapy by excluding patients with insufficient clinical response.

Conditions

Executive Dysfunction

Interventions

Type	Name	Description
DRUG	Atomoxetine	the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
DRUG	methylphenidate	the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg

Timeline

Start date: 2014-02-01
Primary completion: 2014-10-01
Completion: 2014-10-01
First posted: 2015-02-02
Last updated: 2015-02-02

Source: ClinicalTrials.gov record NCT02352051. Inclusion in this directory is not an endorsement.